On the one hand, Tregs can induce immune tolerance and lead to tumor progression by the following mechanisms: secretion of immunosuppressive molecules such as transforming growth factor beta (TGFβ), IL-10, and CCL22; directly cytolysis of NK cells and CD8+ cells; metabolic disruption; and promoting angiogenesis [1, 33–35]. The gene discussed is CCL22; the disease is neoplasm.